ばらお

50代男

[ばらお @nafldr]

@ArturGalata 6？

[NEJM @NEJM]

MASLD has become the most common chronic liver disease worldwide. Giovanni Targher, MD, Luca Valenti, MD (@lucavalenti75), and Christopher D. Byrne, MB, ChB, review the features of the disease as well as pharmacotherapies targeting the associated liver and cardiovascular–renal–metabolic issues.

Learn more in the Review Article “Metabolic Dysfunction–Associated Steatotic Liver Disease” from @univerona, IRCCS Sacro Cuore Don Calabria Hospital, and elsewhere: https://t.co/EJhFlIcXOp

[NEJM @NEJM]

Original Article: Tirzepatide as Compared with Semaglutide for the Treatment of Obesity (SURMOUNT-5 phase 3b trial) https://t.co/mDYfCO3Bqy

@EASOobesity | #ECO2025

[天野 慎介 Shinsuke Amano @shinsuke_amano]

【緊急署名・拡散希望】「高額療養費制度引き上げ反対」石破首相・福岡厚生労働大臣にがんや難病患者・家族の切実な声を届けたい
▼オンライン署名はこちら▼
https://t.co/5cFzzEC1ID

昨日の衆議院本会議で、石破首相より高額療養費制度引き上げ問題について「ゼロ回答」だったことを受け、全国がん患者団体連合会、日本難病・疾病団体協議会、慢性骨髄性白血病患者・家族の会いずみの会が署名呼びかけ団体となり、緊急署名を開始しました。

この緊急署名には賛同人として現時点までに、麻倉未稀さん（歌手、乳がん経験者）秋野暢子さん（女優、食道がん経験者）木山裕策さん（歌手、甲状腺乳頭がん）にもご賛同いただいております。皆さまのご協力を賜りたく、何卒よろしくお願い申し上げます。

[NEJM @NEJM]

In the ELATIVE trial involving patients with primary biliary cholangitis, treatment with elafibranor, a dual PPAR-α and PPAR-δ agonist, led to greater improvements in biochemical indicators of cholestasis than placebo. Full results and Research Summary: https://t.co/dtLMERK89k

[NEJM @NEJM]

Resmetirom is a selective agonist of THR-β. In adults with nonalcoholic steatohepatitis and fibrosis, daily resmetirom (80 mg or 100 mg) was superior to placebo with respect to NASH resolution and fibrosis improvement. Full MAESTRO-NASH trial results: https://t.co/Sa0XRPmU5C

[Nature Medicine @NatureMedicine]

In the phase 3 MAESTRO-NAFLD-1 trial, the liver-targeted thyroid hormone receptor-β selective agonist resmetirom was well tolerated and improved liver biomarkers in adults with nonalcoholic fatty liver disease

https://t.co/qeyfue8hh4

[Scott Isaacs @scottisaacsmd]

New #NAFLD Nomenclature!
Fatty Liver = Steatotic Liver Disease #SLD
NAFLD = #MASLD
NASH = #MASH
MASLD who drink ETOH = #MetALD
Alcohol related liver disease = #ALD
SLD with known cause (drug, Hep C, Wilson, other genetic etc.) = specific etiology SLD
SLD without known metabolic or other risk = cryptogenic SLD
#LiverTwitter
https://t.co/JNtJyAQdtV

[Ramon Bataller @rabataller]

How can we predict clinical outcomes in NAFLD?

Do we need biopsy? Are non-invasive tests good enough?

A study in >2,500 biopsy-proven NAFLD in @LancetGastroHep shows that non-invasive tests are comparable to liver biopsy.

#livertwitter #MedTwitter https://t.co/D7dKjTmSZw

[ばらお @nafldr]

肝臓に線維がたまると肝硬変や肝癌の心配がでてきますが、肝臓の線維化の程度を推測する計算式として、FIB-4が有用であり、年齢と血液検査の数値(AST、ALT、血小板数)から計算します。FIB-4≧1.3の人は病院で一度みてもらうことをおすすめします。https://t.co/mp8GlfKNcW

[ばらお @nafldr]

飲酒量が中間の人はどちらにもあてはまらないのですが、最近は、飲酒量に関係なく代謝異常(メタボ)を合併する脂肪肝のことを代謝機能異常関連脂肪性肝疾患(MAFLD;マッフルディ)と呼ぶこともあります。

[Rohit Loomba @DrLoomba]

Important data on fibrosis progression rate in diabetes from @NAFLDresearch @UCSD_GI @UCSDHealthSci using our #nashcrn cohort— if a patient with diabetes had stage 1 fibrosis today the time to progression to stage 2 is 4 years!! @HealioGastro @AASLDtweets @AmerGastroAssn

[Nature is Amazing ☘️ @AMAZlNGNATURE]

When I'm sad, I like to remember how capybaras are chill as hell pals with the rest of the animal kingdom

[AASLD @AASLDtweets]

Now published in @HEP_Journal: This AASLD Guidance document reflects many advances in the field pertinent to any practitioner caring for patients with #NAFLD and emphasizes advances in noninvasive risk stratification and therapeutics. https://t.co/iisdQqhs75 #LiverTwitter

[NEJM @NEJM]

Acute kidney injury (AKI) is a common condition in patients with cirrhosis. It occurs in up to 50% of hospitalized patients with cirrhosis and in 58% of such patients in the intensive care unit (ICU). 1/10

[NEJM @NEJM]

In a randomized trial involving patients with acute pancreatitis, early aggressive fluid resuscitation resulted in increased fluid overload without improvement in clinical outcomes. https://t.co/syZoPgCM5m

[Andrea Cercek @AndreaCercek]

Very proud of our study published in @NEJM. 100% clinical complete response with dostarlimab alone in mismatch repair-deficient locally advanced #RectalCancer. No radiation or surgery! @ASCO #ASCO22 @MSKCancerCenter https://t.co/sZypoHBtj7

[Juan Pablo (JP) Arab, MD  @juanpabloarab]

Exciting results for #NAFLD field in @NEJM ... 85% had a weight loss of at least 5% with the lower dose (5 mg), 91% with 15mg weekly.
Tirzepatide Once Weekly for the Treatment of Obesity
#LiverTwitter @NoureddinMD @DrLoomba @MarcoArreseMD @LuisAntonioDiaz
https://t.co/uPY8HZ4TIh

[Rohit Loomba @DrLoomba]

Mortality Outcomes by Fibrosis Stage in Non-alcoholic Fatty Liver Disease. A Systematic Review and Meta-Analysis https://t.co/gBB2chYA6Q